Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ponatinib Hydrochloride

FDA-approved product (tablet, oral), marketed as Iclusig, Ponatinib Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ponatinib Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute lymphoblastic leukemia
  • Chronic myelogenous leukemia
  • Lymphoid leukemia
  • Myeloid leukemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bcr-abl tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ponatinib Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ponatinib Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)

    NCT07614022 · start 2026-10

    Registered record
    Registry ID
    NCT07614022
    Conditions
    Philadelphia Positive Acute Lymphoblastic Leukemia
    Interventions
    LP-118
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2030-03
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhiladelphia Positive Acute Lymphoblastic Leukemia
    InterventionLP-118
    PhasePhase 1
    Registry statusNot yet recruiting

  • Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world

    NCT07356960 · start 2026-04-02

    Registered record
    Registry ID
    NCT07356960
    Conditions
    Acute Lymphobkastic Leukemia; Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-04-02
    Completion
    2029-06-30
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphobkastic Leukemia; Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

    NCT06207123 · start 2024-09-13

    Registered record
    Registry ID
    NCT06207123
    Conditions
    Acute Leukemia; Lymphoblastic Leukemia; Lymphoblastic Lymphoma
    Interventions
    LP-118; Ponatinib; Vincristine; Dexamethasone; Methotrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-09-13
    Completion
    2026-12-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Leukemia; Lymphoblastic Leukemia; Lymphoblastic Lymphoma
    InterventionLP-118; Ponatinib; Vincristine; Dexamethasone +1 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

    NCT06390306 · start 2024-07-01

    Registered record
    Registry ID
    NCT06390306
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    Ponatinib; Azacitidine; Venetoclax; Olverembatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-07-01
    Completion
    2027-12-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionPonatinib; Azacitidine; Venetoclax; Olverembatinib
    PhaseNot recorded
    Registry statusRecruiting

  • Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment

    NCT07188428 · start 2024-02-27

    Registered record
    Registry ID
    NCT07188428
    Conditions
    Leukemia, Chronic Myeloid
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-02-27
    Completion
    2024-12-02
    Enrolment
    2,298

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia, Chronic Myeloid
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT

    NCT06061094 · start 2023-07-14

    Registered record
    Registry ID
    NCT06061094
    Conditions
    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    Interventions
    Imatinib; Ponatinib; Blinatumomab; Indication for stem cell transplantation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-07-14
    Completion
    2029-07-01
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia
    InterventionImatinib; Ponatinib; Blinatumomab; Indication for stem cell transplantation
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

    NCT05743465 · start 2021-10-06

    Registered record
    Registry ID
    NCT05743465
    Conditions
    Leukemia
    Interventions
    No Intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-10-06
    Completion
    2022-11-30
    Enrolment
    1,769

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionNo Intervention
    PhaseNot recorded
    Registry statusCompleted

  • Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

    NCT04475731 · start 2021-05-04

    Registered record
    Registry ID
    NCT04475731
    Conditions
    Philadelphia-Positive ALL; Acute Lymphoblastic Leukemia, in Relapse
    Interventions
    Ponatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-05-04
    Completion
    2024-11
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhiladelphia-Positive ALL; Acute Lymphoblastic Leukemia, in Relapse
    InterventionPonatinib
    PhasePhase 2
    Registry statusActive not recruiting

  • Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

    NCT04747912 · start 2021-03-02

    Registered record
    Registry ID
    NCT04747912
    Conditions
    Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia; ph+ Acute Lymphoblastic Leukemia
    Interventions
    Inotuzumab ozogamicin; Dasatinib; Dexamethasone; Methotrexate; Vincristine; Ponatinib; Purinethol (6-Mercaptopurine); Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-03-02
    Completion
    2028-03-01
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoblastic Leukemia; Acute Lymphoblastic Leukemia; ph+ Acute Lymphoblastic Leukemia
    InterventionInotuzumab ozogamicin; Dasatinib; Dexamethasone; Methotrexate +4 more
    PhasePhase 2
    Registry statusRecruiting

  • Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL

    NCT04554459 · start 2021-02-16

    Registered record
    Registry ID
    NCT04554459
    Conditions
    Acute Lymphoblastic Leukemia, Adult; Ph+ ALL; Newly Diagnosed
    Interventions
    Ponatinib 15 MG Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-02-16
    Completion
    2024-07-01
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia, Adult; Ph+ ALL; Newly Diagnosed
    InterventionPonatinib 15 MG Oral Tablet
    PhasePhase 2
    Registry statusTerminated

  • Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia

    NCT04709731 · start 2021-02-01

    Registered record
    Registry ID
    NCT04709731
    Conditions
    Chronic Myeloid Leukemia (CML)
    Interventions
    Ponatinib 15mg QD; Ponatinib 30mg QD
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-02-01
    Completion
    2025-04-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia (CML)
    InterventionPonatinib 15mg QD; Ponatinib 30mg QD
    PhasePhase 2
    Registry statusUnknown

  • Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

    NCT04530565 · start 2021-01-25

    Registered record
    Registry ID
    NCT04530565
    Conditions
    B Acute Lymphoblastic Leukemia With t(9; 22)(q34.1; q11.2); BCR-ABL1
    Interventions
    Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration and Biopsy; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin Hydrochloride; Echocardiography Test; Electrocardiography; Lumbar Puncture; Mesna; Methotrexate; Multigated Acquisition Scan; Ponatinib Hydrochloride; Prednisone; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-01-25
    Completion
    2028-07-01
    Enrolment
    348

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB Acute Lymphoblastic Leukemia With t(9; 22)(q34.1; q11.2); BCR-ABL1
    InterventionBiospecimen Collection; Blinatumomab; Bone Marrow Aspiration and Biopsy; Cyclophosphamide +13 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

    NCT05286528 · start 2020-11-18

    Registered record
    Registry ID
    NCT05286528
    Conditions
    Chronic Myeloid Leukaemia
    Interventions
    Bosutinib; Imatinib; Nilotinib; Dasatinib; Ponatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-11-18
    Completion
    2022-01-31
    Enrolment
    1,484

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukaemia
    InterventionBosutinib; Imatinib; Nilotinib; Dasatinib +1 more
    PhaseNot recorded
    Registry statusCompleted

  • The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

    NCT04591431 · start 2020-10-07

    Registered record
    Registry ID
    NCT04591431
    Conditions
    Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    Interventions
    Erlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab; Lapatinib; Everolimus; Vemurafenib; Cobimetinib; Alectinib; Brigatinib; Palbociclib; Ponatinib; Vismogedib; Itacitinib; Ipatasertib; Entrectinib; Atezolizumab; Nivolumab; Ipilimumab; Pemigatinib; Oncology Drugs; Pralsetinib; Selpercatinib; Talazoparib; Tepotinib; Alpelisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-10-07
    Completion
    2025-06
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    InterventionErlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab +22 more
    PhasePhase 2
    Registry statusUnknown

  • Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

    NCT04188405 · start 2020-05-17

    Registered record
    Registry ID
    NCT04188405
    Conditions
    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions
    Decitabine; Ponatinib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-05-17
    Completion
    2026-06-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Acute Myeloid Leukemia +3 more
    InterventionDecitabine; Ponatinib; Venetoclax
    PhasePhase 2
    Registry statusCompleted